ArticlePDF Available

Linkage analysis and allelic imbalance in human breast cancer kindreds using microsatellite markers from the short arm of chromosome 3

November 1995
Human Genetics 96(4):437-43

DOI:10.1007/BF00191803

Source
PubMed

Authors:

Jon Thor Bergthorsson

University of Iceland

Gudny Eiriksdottir

Hjartavernd

Rosa Bjork Barkardottir

National University Hospital of Iceland

Show all 6 authorsHide

Eight Icelandic breast cancer kindreds were subjected to linkage analyses with respect to 28 microsatellite loci dispersed along the short arm of chromosome 3. Breast tumors derived from these kindreds were concurrently scored for allelic imbalance with ten of the markers. Linkage to most markers could be excluded on the basis of negative LOD scores and haplotype analyses, although some moderately positive LOD scores resulted. A high frequency of imbalance in the familial tumors was seen with two of the markers in comparison with results obtained from sporadic material. The highest frequency (68%) of imbalance was detected with the marker D3S1217, which is located on 3p14.2-p14.1. Imbalance at the D3S1211 locus, which is more telomeric (3p24.2-p22), was not significantly elevated in the familial tumors. We suggest that the genetic defect responsible for breast cancer susceptibility in these families either promotes instability in the 3p14.2-p14.1 region or enhances the selective advantage of such changes.

Content uploaded by Sigurdur Ingvarsson

Content may be subject to copyright.

Content uploaded by Sigurdur Ingvarsson

Content may be subject to copyright.

Molecular Genetics of Breast Cancer

Article

Full-text available

Jun 2003

Sigurdur Ingvarsson

Gene and chromosome changes in breast cancer have been analysed using molecular and cytological methods. No single gene alterations are frequent in breast cancer, but several alterations have been detected, in line with multigenetic disease, although malignant progression in relation to gene changes is poorly documented. The most common tumour suppressor gene mutations, detected in about ¼ of breast tumours are in the TP53 gene, that encodes a transcription factor. Mutations and other alterations in the CDH1 gene, encoding the E-cadherin adhesion protein, in the CHK2 gene, encoding a cell cycle checkpoint kinase, in the BRCA1 and BRCA2 genes, encoding DNA repair proteins and FHIT, encoding a diadenosine hydrolase, will be reviewed. The molecular mechanism behind the frequently detected instability of the genome of breast cancer cells is poorly understood, but some studies have associated it with mutations in the TP53, BRCA1 or BRCA2 genes.

Molecular genetic analysis of non familial renal cell carcinoma

Thesis

Jan 2002

Keith Foster

Human cancers are caused by mutations affecting the products of oncogenes, tumour suppressor genes and DNA repair genes. Identification of tumour suppressor genes that give rise to sporadic cancers has often been achieved by isolating rare familial cancer genes via a reverse genetic approach. Loss of heterozygosity (LOH) studies have suggested that somatic mutations of a tumour suppressor gene or genes on 3p are critical in the pathogenesis of non familial renal cell carcinoma (RCC). Different studies have implicated differing critical loci. To further investigate the role that 3p genes may have in the tumourigenesis of sporadic RCC, 55 paired normal-tumour DNA's were analysed for allele loss, and at regions of known or putative tumour suppressor genes on chromosomes 5, 11, 17 and 22. 64% (35/55) of informative tumours displayed LOH of at least one or more loci on 3p, compared with 13% at the p53 locus and 6% at 17q21. LOH at 5q21 and 22q was uncommon. The LOH study identified three critical regions of loss on chromosome 3, at 3p25-26, 3p21 and at 3p12-14. The von Hippel Lindau (VHL) tumour suppressor gene was isolated in 1993. It maps to chromosome 3p25-26, coincident with a region of LOH. VHL disease manifests as a variety of benign and malignant neoplasms, and is the most common cause of familial RCC. The role that mutations of the VHL gene may have in the pathogenesis of sporadic RCC was investigated. 99 primary RCC were analysed for SSCP and heteroduplex formations. Somatic mutations were identified in 46% (30/65) sporadic RCC's with 3p LOH and in 3% (1/34) with no 3p LOH. Histology was available for 59 tumours: 42% (18/43) of RCC with a clear cell phenotype had VHL mutations, whereas none of 16 with a non clear cell phenotype (8 chromophilic, 3 chromophobic, and 5 oncocytomas) had VHL mutations (χ2=7.77, p<0.025). These results confirm that mutations in the VHL gene are events that initiate the development of RCC. 3p allele loss is a frequent event in gonadal tumours. 60 gonadal (36 ovarian and 24 testicular) tumours were analysed for VHL gene mutations and 3p allele loss. 3p LOH was detected in 38% (10/26) of informative ovarian and 56% (7/13) testicular tumours, but no VHL mutations were found. This suggests that chromosome 3p tumour suppressor gene(s) other than VHL are involved in gonadal tumourigenesis.

The Role of Estrogen in Breast Cancer

Chapter

Jan 2004

Intensive epidemiological studies have identified a number of genetic risk factors associated with breast cancer, including evidence of BRCA1 and BRCA2 susceptibility genes, familiar history of cancer in the breast, ovary or endometrium and individual history of breast diseases [1]. An increased risk has also been associated with early onset of menstruation, nulliparity or delayed first childbirth, short duration of breast feeding, late menopause, use of hormone replacement therapy and increased bone density [2–4]. A principal culprit common for all these endocrine-related risk factors is the prolonged exposure to female sex hormones [5–8]. The hormonal influences have been mainly attributed to unopposed exposure to elevated levels of estrogens [5], as has been indicated for a variety of female cancers, namely, vaginal, hepatic and cervical carcinomas [9–11]. Exposure to estrogens, particularly during the critical developmental periods (e.g., in utero, puberty, pregnancy, menopause), also affects affective behaviors (e.g., depression, aggression, alcohol intake) and increases breast cancer risk [12].

Tumor Suppressor Genes on Human Chromosome 3 and Cancer Pathogenesis

Article

Full-text available

Jul 2005

Sigurdur Ingvarsson

The short arm of chromosome 3 is frequently altered in human cancers of different tissue origin. Certain regions on the chromosome arm 3p have been defined by deletion studies in human cancer cells and tissues. Also, regions at 3p are eliminated in microcell hybrids parallel to increased tumongenicity in immunosuppressed mice. We have analysed chromosome instability and several genes involved in tumor pathogenesis at 3p, such as VHL, RIITGFB, CATNB, MLH1 and FHIT. By studying eleven tumor types, we have shown that the importance of CER1 (common eliminated region 1) transgresses tissue specificity. Comparative studies on losses of VHL, FHIT/FRA3B and CER1 show that the CER1 region is preferably lost in human tumors. Alterations of FHIT are associated with reduced survival of breast and colon cancer patients. The FHIT gene is located at the constitutive fragile region, FRA3B. Chromosome 3, particularly FHIT, is unstable in breast cancer patients who have germ line mutation in the BRCA2 gene. The chromosome instability in BRCA2 tumors reflects the DNA repair mechanism of the gene product Brca2. It can be concluded that our results reflect a synergism of tumor suppressor gene (TSG) losses at the chromosome 3p region in relation to the biological behavior of tumor cells and tumor pathogenesis.

Estrogens and Breast Cancer

Article

Jul 2002

In the present work we demonstrate that estradiol and its metabolites mainly 4-OH estradiol are able to induce transformation phenotypes in the human breast epithelial cells (HBEC) MCF-10F. This cell line is a spontaneously immortalized HBEC that does not contain measurable level of ER alpha or ER beta. Short-term treatment of these cells with physiological doses of 17-beta estradiol induces anchorage independent growth, colony formation in agar methocel, and reduces ductulogenic capacity in collagen gel, all phenotypes whose expression is indicative of neoplastic transformation. Physiological doses of 4-OH-E2 (0.007nM) induces transformation phenotypes that are not abrogated by the pure antiestrogen ICI.

Carcinogenicity of estrogens in human breast epithelial cells1

Article

Jul 2001
APMIS

Epidemiological and clinical evidences indicate that breast cancer risk is associated with prolonged ovarian function that results in elevated circulating levels of steroid hormones. Principal among these is estrogen, which is associated with two important risk factors, early onset of menarche and late menopause. However, up to now there is no direct experimental evidence that estrogens are responsible of the initiation of human breast cancer. We postulate that if estrogens are causative agents of this disease, they should elicit in human breast epithelial cells (HBEC) genomic alterations similar to those exhibited by human breast cancers, such as DNA amplification and loss of genetic material representing tumor suppressor genes. These effects could result from binding of the hormone to its nuclear receptors (ER) or from its metabolic activation to reactive metabolites. This hypothesis was tested by treating with the natural estrogen 17β-estradiol (E2) and the synthetic steroid diethylstilbestrol (DES) MCF-10F cells, a HBEC line that is negative for ER. Cells treated with the chemical carcinogen benzo (a) pyrene (BP) served as a positive control of cell transformation. BP-, E2-, and DES-treated MCF-10F cells showed increases in survival efficiency and colony efficiency in agar methocel, and loss of ductulogenic capacity in collagen gel. The largest colonies were formed by BP-treated cells, becoming progressively smaller in DES- and E2-treated cells. The loss of ductulogenic capacity was maximal in BP-, and less prominent in E2- and DES-treated cells. Genomic analysis revealed that E2- and DES-treated cells exhibited loss of heterozygosity in chromosomes 3 and 11, at 3p21, 3p21–21.2, 3p21.1–14.2, and 3p14.2–14.1, and at 11q23.3 and 11q23.1–25 regions, respectively. It is noteworthy that these loci are also affected in breast lesions, such as ductal hyperplasia, carcinoma in situ, and invasive carcinoma. Our data are the first ones to demonstrate that estrogens induce in HBEC phenotypic changes indicative of cell transformation and that those changes are associated with significant genomic alterations that might unravel new pathways in the initiation of breast cancer.

Identification of a breast tumor with microsatellite instability in a potential carrier of the hereditary non-polyposis colon cancer trait

Article

Full-text available

Jul 1995

Allelic expansion at microsatellite loci in colorectal tumor DNA indicates a genomic instability caused by defects in DNA mismatch repair. This is observed in a high proportion of tumors from individuals affected by hereditary non-polyposis colorectal carcinoma, but to a lesser extent in sporadic colorectal tumors. In this study we screened 46 colorectal tumors for replication errors (RER). Tumors from six patients were found to be RER positive, two of which had a marked family history of colon cancer. In both cases the RER + phenotype was detected in colon tumors from other family members, suggesting a germline mutation in mismatch repair genes. Additionally, RER + phenotype, distinct from that of the colon and sporadic breast tumors, was found in malignant breast tissue from the mother of one proband.

Chromosome aberrations in prophylactic mastectomies from women belonging to breast cancer families

Article

Jul 1996

Short-term cultures of samples from eight prophylactic mastectomies from five unrelated women who were genetically predisposed to breast cancer were analyzed cytogenetically. Clonal chromosome abnormalities were detected in five breasts. Three samples from two women had aberrations involving the short arm of chromosome 3, with a breakpoint in 3p14 in common. Three samples from three women had rearrangements of 1q. Two of them, one of which also displayed a 3p14 rearrangement, shared a breakpoint in 1q41. Both 1q41 and, in particular, 3p14 have been reported to be rearranged frequently in malignant breast proliferations. Whether alterations of genes in these bands are essential in mammary tumorigenesis and, if so, whether they are equally important in sporadic and in hereditary cases remains to be explored.

Deletions of the Short Arm of Chromosome 3 in Solid Tumors and the Search for Suppressor Genes

Article

Feb 1997
ADV CANCER RES

This chapter discusses the methodological advantages and limitations of the various approaches used to localize tumor suppressor genes on 3p, the short arm of chromosome 3. The results of functional assays of tumor suppression by transfer of part of chromosome 3 into tumor cell lines are also discussed. The two approaches routinely used to detect deletions in tumor cells or tumor-derived cell lines as a possible indication of the location of a tumor suppressor gene are karyotyping and analysis of loss of heterozygosity. The role of 3p in tumor suppression is confirmed by observations that spontaneous tumorigenic mutants in nontumorigenic immortalized cell lines show loss of parts of 3p. Such cellular models offer an alternative approach to define the 3p regions involved in some specific tumors. In several types of tumor, an increase in the size of 3p deletions with the stage of disease is observed. Searches for genes are in progress for some of the more precisely defined smaller regions with presumed tumor suppressor activity on 3p. The only gene on 3p considered as a tumor suppressor, VHL, is identified because of its involvement in a hereditary cancer syndrome, allowing the collection of families and the application of linkage analysis to pinpoint the gene.

The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B

Article

Jul 1997
Biochim Biophys Acta

Mapping of chromosome 3 alterations in human breast cancer using microsatellite PCR markers: Correlation with clinical variables

Article

Full-text available

Feb 1995

Human breast tumours were analyzed with polymorphic microsatellite markers specific to chromosome 3p. Allelic imbalance (AI) was observed in 34% of the tumours. Microsatellite markers from two regions showed higher percentage of imbalance suggesting the presence of tumour suppressor genes or genes important for malignancy. Microsatellite instability was also found, implying errors in DNA replication. No significant correlation was found between AI and conventional prognostic variables. However, a striking correlation was found between AI and tumour S-phase fraction; AI was also significantly correlated with low steroid receptor content. A multivariate model including prognostic variables, showed that AI was without exception a significant prognostic variable; patients having tumours with AI had approximately a four-fold increase in relative risk of death. We conclude that screening for 3p deletions gives prognostic information and further investigations should reveal whether this finding could assist in treatment of the disease.

Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome

Article

Full-text available

Nov 1992

A predisposing gene for breast and ovarian cancer has recently been mapped to chromosome 17q12-21. If this gene is a tumour suppressor gene, allele losses would be expected in the tumours of affected family members and the losses should affect the wild-type chromosome, reflecting the need for inactivation of the wild-type allele at the predisposing locus. In four multiple case breast-ovarian cancer families, we have found that in each of nine tumours which showed allele losses, the losses were from the wild-type chromosome. This suggests that the putative 'breast-ovarian' cancer gene is indeed a tumour suppressor gene.

BRCA1 Mutations in Primary Breast and Ovarian Carcinomas

Article

Oct 1994

Loss of heterozygosity data from familial tumors suggest that BRCA1, a gene that confers susceptibility to ovarian and early-onset breast cancer, encodes a tumor suppressor. The BRCA1 region is also subject to allelic loss in sporadic breast and ovarian cancers, an indication that BRCA1 mutations may occur somatically in these tumors. The BRCA1 coding region was examined for mutations in primary breast and ovarian tumors that show allele loss at the BRCA1 locus. Mutations were detected in 3 of 32 breast and 1 of 12 ovarian carcinomas; all four mutations were germline alterations and occurred in early-onset cancers. These results suggest that mutation of BRCA1 may not be critical in the development of the majority of breast and ovarian cancers that arise in the absence of a mutant germline allele.

Crockford, G. P. and The Breast Cancer Linkage Consortium, Genetic linkage analysis in familial breast and ovarian cancer-Results from 214 families

Article

Apr 1993
AM J HUM GENET

This paper reports the results of a collaborative linkage study involving 214 breast cancer families, including 57 breast-ovarian cancer families; this represents almost all the known families with 17q linkage data. Six markers on 17q, spanning approximately 30 cM, were typed in the families. The aims of the study were to define more precisely the localization of the disease gene, the extent of genetic heterogeneity and the characteristics of linked families and to estimate the penetrance of the 17q gene. Under the assumption of no genetic heterogeneity, the strongest linkage evidence was obtained with D17S588. Multipoint linkage analysis allowing for genetic heterogeneity provided evidence that the predisposing gene lies between the markers D17S588 and D17S250, an interval whose genetic length is estimated to be 8.3 cM in males and 18.0 cM in females. This position was supported over other intervals by odds of 66:1. The location of the gene with respect to D17S579 could not be determined unequivocally. Under the genetic model used in the analysis, the best estimate of the proportion of linked breast-ovarian cancer families was 1.0 (lower LOD -- 1 limit 0.79). In contrast, there was significant evidence of genetic heterogeneity among the families without ovarian cancer, with an estimated 45% being linked. These results suggest that a gene(s) on chromosome 17q accounts for the majority of families in which both early-onset breast cancer and ovarian cancer occur but that other genes predisposing to breast cancer exist. By examining the fit of the linkage data to different penetrance functions, the cumulative risk associated with the 17q gene was estimated to be 59% by age 50 years and 82% by age 70 years. The corresponding estimates for the breast-ovary families were 67% and 76%, and those for the families without ovarian cancer were 49% and 90%; these penetrance functions did not differ significantly from one another. 42 refs., 5 figs., 2 tabs.

Molecular cloning: A laboratory manual, second ed

Article

Jan 1989

Dinucleotide repeat polymorphism in the human thyroid hormone receptor β gene (THRB) on chromosome 3

Article

Dec 1991

Molecular Cloning: A Laboratory Manual

Chapter

Jan 1983

Isolation and characterization of 19 dinucleotide repeat polymorphisms on chromosome 3p

Article

Jun 1992

We have screened cosmids on chromosome 3p for (dC-dA)n.(dG-dT)n dinucleotide-repeat sequences. Eighty-nine of 155 cosmids (58%) contained (dC-dA)n.(dG-dT(n repeats as determined by colony hybridization with a (dG-dT)10 oligonucleotide probe; 29 of these were subcloned and the sequences flanking the dinucleotide repeats were determined. Nineteen of the 24 loci examined for polymorphisms by PCR were found to be polymorphic with heterozygosities ranging from 3% to 86%. These dinucleotide repeat polymorphisms will be useful markers for high-resolution mapping of genes that have been localized to 3p, including tumour suppressor genes associated with several types of cancer and genes responsible for various hereditary disorders, such as von Hippel-Lindau disease.

A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome

Article

Nov 1992

Breast cancer in men is rare--among the risk factors that have been identified are a family history of breast cancer and evidence of androgen insufficiency. We report a family in which two brothers who both developed breast cancer had clinical and endocrinological evidence of androgen resistance. Sequence analysis revealed a mutation in the androgen receptor gene on the X chromosome, within the region encoding the DNA binding domain. This is the first report of a germline mutation in a member of the steroid/thyroid hormone receptor superfamily associated with the development of cancer.

Three distinct regions involved in 3p deletion in human cancer

Article

Apr 1992
ONCOGENE

The 3p deletion was first noted by cytogenetic analysis and was later confirmed by several independent studies using restriction fragment length polymorphism (RFLP) probes. As an initial step towards positional cloning (reverse genetics) of the tumor-suppressor gene(s) on 3p, a detailed analysis of the minimum deleted region(s) on 3p was performed with 13 RFLP probes and 48 paired human lung cancer samples. All nine small-cell lung cancer cases (100%) and 31 of 39 non-small-cell lung cancer cases (79%) showed allelic loss at one or more loci mapped on 3p. We show here that three distinct regions on 3p appear to be frequently deleted in lung cancer. These regions include 3p25, 3p21.3 and 3p14-cen. The present study should warrant future work focusing on these chromosomal regions on 3p, and may ultimately lead to the isolation of tumor-suppressor genes involved in the pathogenesis of lung cancer.